Back

EASL-ILC 2021 - International Liver Congress of the European Association for the Study of the Liver (Virtual Meeting)

Jun 23 - Jun 26, 2021 | AmsterdamNetherlands

LARVOL is not affiliated with International Liver Congress of the European Association for the Study of the Liver (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Top Products
Show More
Condition
Product
MOA
Trial Name/ID

Showing 104 abstracts linked to Trials

[VIRTUAL] Checkmate 040 Cohort 5: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma and associations between baseline biomarker analyses and outcomes

[VIRTUAL] Radiological and pathological response to neoadjuvant Nivolumab in patients with BCLC A HCC treated by curative percutaneous irreversible electroporation: preliminary report from the NIVOLEP trial (NCT03630640)

[VIRTUAL] A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL

[VIRTUAL] Results of the therapetuic cancer vaccine HepaVac-101 clinical trial in HCC patients

[VIRTUAL] IMbrave150: exploratory efficacy and safety results of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)

[VIRTUAL] Hepatic arterial infusion chemotherapy in combination with PD-1 inhibitor as conversion therapy in locally advanced, potentially resectable hepatocellular carcinoma: A phase II study

[VIRTUAL] Beta-blockers to prevent decompensation of cirrhosis: an emulation of the PREDESCI trial

  • Poster

[VIRTUAL] A single assessment of acute hemodynamic response to intravenous propranolol predicts hepatic decompensation in cirrhotic patients with portal hypertension

  • Poster

[VIRTUAL] Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure

  • Poster

[VIRTUAL] Treatment of hepatorenal syndrome type 1 with terlipressin reduces need for renal replacement therapy post-liver transplantation

  • Oral

[VIRTUAL] Terlipressin improves renal replacement therapy-free survival in hepatorenal syndrome type 1

  • Poster

[VIRTUAL] COMPARISON OF 20% ALBUMIN VERSUS CRYSTALLOID PLASMALYTE FOR FLUID RESUSCITATION IN CIRRHOTICS WITH SEPSIS INDUCED HYPOTENSION AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL

  • Oral

[VIRTUAL] Algorithm combining fat-free muscle index and total spontaneous portosystemic shunt area indentifies high-risk cirrhotic patients

  • Oral

[VIRTUAL] Albumin dysfunction correlates with disease markers in patients with decompensated cirrhosis

  • Poster

[VIRTUAL] Nutritional supplementation with B-Hydroxy-B-methylbutyrate (HMB) in malnourished cirrhotic patients

  • Poster